Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-centre, Parallel Group, Open Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Administered for up to Three Consecutive Days to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk or Extremities

NCT01325688 is registered in ClinicalTrials.gov with Peplin as lead sponsor.

NCT NCT01325688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01325688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-centre, Parallel Group, Open Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Administered for up to Three Consecutive Days to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk or Extremities
Lead sponsor
Peplin
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
March 31, 2012
Enrollment
75 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

superficial basal cell carcinoma